|
1
|
Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.
|
Clin Cancer Res
|
2007
|
1.60
|
|
2
|
DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.
|
Cancer Res
|
2009
|
0.99
|
|
3
|
Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures.
|
Cancer Res
|
2002
|
0.92
|
|
4
|
Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
|
Radiat Res
|
2007
|
0.88
|
|
5
|
Unsymmetrical DNA cross-linking agents: combination of the CBI and PBD pharmacophores.
|
J Med Chem
|
2003
|
0.80
|
|
6
|
Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.
|
Cancer Biol Ther
|
2015
|
0.79
|
|
7
|
In vitro and in vivo models for evaluation of GDEPT: quantifying bystander killing in cell cultures and tumors.
|
Methods Mol Med
|
2004
|
0.78
|
|
8
|
Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
|
J Med Chem
|
2004
|
0.78
|
|
9
|
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
|
J Med Chem
|
2007
|
0.77
|
|
10
|
Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
|
J Med Chem
|
2003
|
0.75
|